Teva Pharmaceuticals USA Inc.'s suit against the US FDA aims to obtain 180-day exclusivity for its generic version of Allergan PLC's Restasis (cyclosporine) and to eliminate the agency's new policy redefining "first applicant."
Teva's complaint is in response to a letter FDA issued in July to applicants of abbreviated new drug applications...




